284 related articles for article (PubMed ID: 24210078)
1. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
2. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
5. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
8. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
10. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Giralt J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1430-6. PubMed ID: 24582914
[TBL] [Abstract][Full Text] [Related]
11. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
[TBL] [Abstract][Full Text] [Related]
12. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
[TBL] [Abstract][Full Text] [Related]
15. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
[TBL] [Abstract][Full Text] [Related]
16. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
19. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.
Hong TS; Moughan J; Garofalo MC; Bendell J; Berger AC; Oldenburg NB; Anne PR; Perera F; Lee RJ; Jabbour SK; Nowlan A; DeNittis A; Crane C
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):29-36. PubMed ID: 26163334
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]